CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The CCTG PA.7 trial: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma met its target accrual of 180 patients on 26-JUL-2018 and is now officially closed to accrual.
The DTL has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network Trial (NCTN) where CCTG is using the DTL is the BLC.4 trial. An active DTL is now a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other upcoming studies that will be using the DTL initially include MAC.24 and REC.4.
The Canadian Cancer Trials Group (CCTG) Operations and Statistical Centre (OSC), based at the Queen’s University Cancer Research Institute in Kingston, Ontario is seeking a physician with hematology or oncology training with demonstrated interest and experience with developing and cancer therapy trials.
Senior investigators work at the OSC with members of the investigational new drug and disease-specific and trial endpoint committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda.
The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research.
The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC). Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.
The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.
